Risperidone - Isotope Labelled Standards
References
FAQ's
References
- Kennis, Ludo Edmond Josephine; Vandenberk, Jan, 1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives, Janssen Pharmaceutica N. V., Belgium, EP196132B1, August 12, 1992
- Woestenborghs, Robert; Lorreyne, Willy; Van Rompaey, Frank; Heykants, Jos, Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography, Journal of Chromatography, Biomedical Applications, Volume: 583, Issue: 2, Pages: 223-30, 1992
- Aravagiri, Manickam; Marder, Stephen R., Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry, Journal of Mass Spectrometry, Volume: 35, Issue: 6, Pages: 718-724, 2000
Frequently Asked Questions
What is the detection process of Risperidone impurities?
Risperidone impurities are detected using analytical techniques such as high-performance liquid chromatography (HPLC).
How are Risperidone impurities monitored during synthesis?
Risperidone impurities are monitored during synthesis through rigorous quality control measures and analytical testing at various stages to ensure impurity levels remain within acceptable limits.
Can Risperidone impurities harm the effectiveness of the drug?
Risperidone impurities can potentially influence the effectiveness of the drug.
What are the temperature conditions required to store Risperidone impurities?
Risperidone impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.